In the study, 35 patients were treated with PC chemotherapy. The study has been completed, analyzed and published. With PC therapy alone, the median progression-free survival was 14 months and the median overall survival was 30 months. The detection of an IDH-1 mutation and the absence of a bihemispheric symmetrical pattern of involvement on MRI were identified as independent positive prognostic factors in a multivariate analysis. The NOA-05 study is the only prospective therapy study for gliomatosis cerebri to date and establishes PC therapy alone as a reasonable first-line therapy for gliomatosis cerebri.